UBS AM’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-64,416
| Closed | -$1.02M | – | 2673 |
|
|
2024
Q4 | $1.02M | Buy |
64,416
+13,864
| +27% | +$219K | ﹤0.01% | 2352 |
|
|
2024
Q3 | $2.94M | Buy |
50,552
+2,271
| +5% | +$132K | ﹤0.01% | 1831 |
|
|
2024
Q2 | $2.21M | Buy |
48,281
+31,146
| +182% | +$1.42M | ﹤0.01% | 1945 |
|
|
2024
Q1 | $1.13M | Hold |
17,135
| – | – | ﹤0.01% | 1946 |
|
|
2023
Q4 | $681K | Buy |
17,135
+6,050
| +55% | +$241K | ﹤0.01% | 2220 |
|
|
2023
Q3 | $353K | Sell |
11,085
-6,050
| -35% | -$193K | ﹤0.01% | 2394 |
|
|
2023
Q2 | $732K | Hold |
17,135
| – | – | ﹤0.01% | 2149 |
|
|
2023
Q1 | $732K | Hold |
17,135
| – | – | ﹤0.01% | 2149 |
|
|
2022
Q4 | $823K | Hold |
17,135
| – | – | ﹤0.01% | 1951 |
|
|
2022
Q3 | $645K | Buy |
17,135
+6,050
| +55% | +$228K | ﹤0.01% | 2220 |
|
|
2022
Q2 | $306K | Buy |
11,085
+3,075
| +38% | +$85K | ﹤0.01% | 2476 |
|
|
2022
Q1 | $436K | Hold |
8,010
| – | – | ﹤0.01% | 2505 |
|
|
2021
Q4 | $469K | Buy |
+8,010
| New | +$469K | ﹤0.01% | 2587 |
|
|
2021
Q2 | – | Sell |
-7,000
| Closed | -$431K | – | 2770 |
|
|
2021
Q1 | $431K | Buy |
7,000
+900
| +15% | +$55.4K | ﹤0.01% | 2432 |
|
|
2020
Q4 | $430K | Buy |
+6,100
| New | +$430K | ﹤0.01% | 2339 |
|